Enobosarm

Many biotechs that rose during the pandemic have faced challenges as their COVID-19 candidates faltered. CureVac, after its mRNA vaccine's low efficacy, restructured and partnered with GSK. Novavax, despite FDA approval, struggled with uptake and faced a clinical hold on its flu/COVID shot. Inovio Pharmaceuticals, once a frontrunner with DNA-based tech, faced controversy and delayed its FDA application. Veru's antiviral sabizabulin was denied EUA and now focuses on GLP-1 related treatments.

Veru Inc. will present at ObesityWeek on November 5, 2024, discussing enobosarm's potential to optimize weight loss. The Phase 2b clinical trial evaluates enobosarm's safety and efficacy in preserving muscle and augmenting fat loss in sarcopenic obese patients. Topline results are expected in January 2025, with extension study results in Q2 2025.

Pharmaceutical companies are racing to develop obesity drugs more potent than Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Key trials in the next six months will reveal contenders like Lilly's Zepbound, Novo's dual-acting cagrisema, Amgen's maritide, and Roche's GLP-1 pill CT-996. Additionally, efforts to preserve muscle mass and explore new drug targets like CB1 inhibition are underway.